Literature DB >> 23467792

Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study.

Takeshi Nishijima1, Takuro Shimbo, Hirokazu Komatsu, Misao Takano, Junko Tanuma, Kunihisa Tsukada, Katsuji Teruya, Hiroyuki Gatanaga, Yoshimi Kikuchi, Shinichi Oka.   

Abstract

Kidney tubulopathy is a well-known adverse event of antiretroviral agent tenofovir. A cross-sectional study was conducted to compare the diagnostic accuracy of five tubular markers, with a collection of abnormalities in these markers as the reference standard. The study subjects were patients with HIV-1 infection on ritonavir-boosted darunavir plus tenofovir/emtricitabine with suppressed viral load. Kidney tubular dysfunction (KTD) was predefined as the presence of at least three abnormalities in the following five parameters: β2-microglobulinuria (β2M), α1-microglobulinuria (α1M), high urinary N-acetyl-β-D-glucosaminidase (NAG), fractional excretion of phosphate (FEIP), and fractional excretion of uric acid (FEUA). Receiver operating characteristic curves and areas under the curves (AUC) were estimated, and the differences between the largest AUC and each of the other AUCs were tested using a nonparametric method. The cutoff value of each tubular marker was determined using raw data of 100% sensitivity with maximal specificity. KTD was diagnosed in 19 of the 190 (10%) patients. The AUCs (95% CIs) of each tubular marker were β2M, 0.970 (0.947-0.992); α1M, 0.968 (0.944-0.992); NAG, 0.901 (0.828-0.974); FEIP, 0.757 (0.607-0.907), and FEUA, 0.762 (0.653-0.872). The AUCs of β2M and α1M were not significantly different, whereas those of the other three markers were smaller. The optimal cutoff values with 100% sensitivity were 1,123 μg/gCr (β2M, specificity 89%), 15.4 mg/gCr (α1M, specificity 87%), 3.58 U/gCr (NAG, specificity 46%), 1.02% (FEIP, specificity 0%), and 3.92% (FEUA, specificity 12%). Urinary β2M and α1M are potentially suitable screening tools for tenofovir-induced KTD. Monitoring either urinary β2M or α1M should be useful in early detection of tenofovir nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23467792     DOI: 10.1007/s10156-013-0576-y

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  12 in total

1.  Risk factors: Individual assessment of CKD risk in HIV-positive patients.

Authors:  Rebecca Scherzer; Michael G Shlipak
Journal:  Nat Rev Nephrol       Date:  2015-05-12       Impact factor: 28.314

Review 2.  Biomarkers of Drug-Induced Kidney Toxicity.

Authors:  Benjamin R Griffin; Sarah Faubel; Charles L Edelstein
Journal:  Ther Drug Monit       Date:  2019-04       Impact factor: 3.681

Review 3.  Tenofovir nephrotoxicity among Asians living with HIV: review of the literature.

Authors:  Takeshi Nishijima; Hiroyuki Gatanaga; Shinichi Oka
Journal:  Glob Health Med       Date:  2019-12-31

4.  Tenofovir disoproxil fumarate initiation and changes in urinary biomarker concentrations among HIV-infected men and women.

Authors:  William R Zhang; Rebecca Scherzer; Michelle M Estrella; Simon B Ascher; Anthony Muiru; Vasantha Jotwani; Carl Grunfeld; Chirag R Parikh; Deborah Gustafson; Seble Kassaye; Anjali Sharma; Mardge Cohen; Phyllis C Tien; Derek K Ng; Frank J Palella; Mallory D Witt; Ken Ho; Michael G Shlipak
Journal:  AIDS       Date:  2019-03-15       Impact factor: 4.177

5.  Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection.

Authors:  Hongzhao Li; Robert W Omange; Binhua Liang; Nikki Toledo; Yan Hai; Lewis R Liu; Dane Schalk; Jose Crecente-Campo; Tamara G Dacoba; Andrew B Lambe; So-Yon Lim; Lin Li; Mohammad Abul Kashem; Yanmin Wan; Jorge F Correia-Pinto; Michael S Seaman; Xiao Qing Liu; Robert F Balshaw; Qingsheng Li; Nancy Schultz-Darken; Maria J Alonso; Francis A Plummer; James B Whitney; Ma Luo
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

6.  HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study.

Authors:  Vasantha Jotwani; Rebecca Scherzer; Michelle M Estrella; Lisa P Jacobson; Mallory D Witt; Frank J Palella; Bernard Macatangay; Michael Bennett; Chirag R Parikh; Joachim H Ix; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2016-06-08       Impact factor: 8.860

7.  Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients.

Authors:  Lisa Hamzah; Amanda Samarawickrama; Lucy Campbell; Matthew Pope; Keith Burling; Martin Fisher; Yvonne Gilleece; Karen Walker-Bone; Frank A Post
Journal:  AIDS       Date:  2015-09-10       Impact factor: 4.177

8.  Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.

Authors:  Takeshi Nishijima; Hiroyuki Gatanaga; Takuro Shimbo; Hirokazu Komatsu; Tomoyuki Endo; Masahide Horiba; Michiko Koga; Toshio Naito; Ichiro Itoda; Masanori Tei; Teruhisa Fujii; Kiyonori Takada; Masahiro Yamamoto; Toshikazu Miyakawa; Yoshinari Tanabe; Hiroaki Mitsuya; Shinichi Oka
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

Review 9.  Urinary Markers of Tubular Injury in HIV-Infected Patients.

Authors:  Temesgen Fiseha; Angesom Gebreweld
Journal:  Biochem Res Int       Date:  2016-07-17

10.  Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.

Authors:  Kyoung Hwa Lee; Ji Un Lee; Nam Su Ku; Su Jin Jeong; Sang Hoon Han; Jun Yong Choi; Young Goo Song; June Myung Kim
Journal:  Yonsei Med J       Date:  2017-07       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.